Contract Research

At Biogenomics, our core competency lies in our ability to rapidly develop high expression- high quality Biopharmaceuticals, using our proprietary platform technology. The platform technology comprises of vectors that generate high yield Super-Producer Cell Lines. Our Process Development is robust with principles of 'Quality-by-Design' (QbD) which are critical for subsequent regulatory clearances.

Our clients are assured of the best quality of research which is extremely cost-effective with strict adherence to confidentiality and intellectual property rights.

The scope of Contract Research services offered extends over a wide spectrum of activities and includes the following:

Molecular cloning and expression of genes in bacteria, yeast and other mammalian cells
Strain development and characterization of Master Cell Banks
Fermentation and purification process development
Downstream process development as per cGMP
Formulation development and Stability studies for Biopharmaceuticals

Contract research is undertaken at Biogenomics’ sprawling 20,000 sq. ft. R&D center, which includes an 9000 sq. ft. of class 100,000 area. The center is well-equipped with the latest world class instruments and other support facilities.

Vision & Mission

Biogenomics is a Science driven enterprise. Led by eminent scientists, business professionals and a focussed team of molecular biologists, microbiologists and protein engineers, Biogenomics has, in a short span of 10 years, developed dozens of Biopharmaceuticals and Biotech products.

Biogenomics has a thorough understanding of both microbial and mammalian technologies and an ability to develop own clones and cell lines. The resulting unique platform technology has allowed Biogenomics to rapidly deliver efficient, cost-effective, scalable and internationally acceptable technologies and products.

With fully integrated ‘Bench to Manufacturing’ facilities, Biogenomics ensures a quick turnaround, adaptive technology and is capable of full-scale manufacturing.

Biogenomics is consistently able to meet and exceed all regulatory standards in its products, processes and facilities.

Our proven capability to research, develop, customize and manufacture high-value biopharmaceuticals is an endorsement of our ability to meet global benchmarks. Our strengths lie in our scientific forte, proprietary technologies and state-of-the-art facilities.

Team

The Company is run by dynamic Board of Directors headed by Mr. R M Parakh, Chairman and Managing Director. Mr. Parakh is a well known and highly respected prominent NRI settled in Oman over the last 32 years. He is also the Managing Director - Finance of Saud Bahwan Group, one of largest trading house in the Gulf having annual turnover of US$ 4.5 Billion.

Biogenomics has a thorough understanding of both microbial and mammalian technologies and an ability to develop own clones and cell lines. The resulting unique platform technology has allowed Biogenomics to rapidly deliver efficient, cost-effective, scalable and internationally acceptable technologies and products.

With fully integrated ‘Bench to Manufacturing’ facilities, Biogenomics ensures a quick turnaround, adaptive technology and is capable of full-scale manufacturing.

Biogenomics is consistently able to meet and exceed all regulatory standards in its products, processes and facilities.

Our proven capability to research, develop, customize and manufacture high-value biopharmaceuticals is an endorsement of our ability to meet global benchmarks. Our strengths lie in our scientific forte, proprietary technologies and state-of-the-art facilities.

Strength

The Company is run by dynamic Board of Directors headed by Mr. R M Parakh, Chairman and Managing Director. Mr. Parakh is a well known and highly respected prominent NRI settled in Oman over the last 32 years. He is also the Managing Director - Finance of Saud Bahwan Group, one of largest trading house in the Gulf having annual turnover of US$ 4.5 Billion.

Biogenomics has a thorough understanding of both microbial and mammalian technologies and an ability to develop own clones and cell lines. The resulting unique platform technology has allowed Biogenomics to rapidly deliver efficient, cost-effective, scalable and internationally acceptable technologies and products.

With fully integrated ‘Bench to Manufacturing’ facilities, Biogenomics ensures a quick turnaround, adaptive technology and is capable of full-scale manufacturing.

Biogenomics is consistently able to meet and exceed all regulatory standards in its products, processes and facilities.

Our proven capability to research, develop, customize and manufacture high-value biopharmaceuticals is an endorsement of our ability to meet global benchmarks. Our strengths lie in our scientific forte, proprietary technologies and state-of-the-art facilities.